How many portfolio companies does Andera Partners have?

Andera Partners has 119 active portfolio companies and 182 completed exits and 25 funds tracked on GP Intel.

Where is Andera Partners headquartered?

Andera Partners is headquartered in Paris, France.

What is Andera Partners's assets under management?

Andera Partners manages approximately €5.3B in assets under management.

Home/GPs/Andera Partners

Andera Partners

Paris, France·anderapartners.com

AUM

€5.3B

Funds

Portfolio

119

Exits

182

Key facts

HQParis, France

Websiteanderapartners.com

Recent exits

Healthcare · 2026

Healthcare · 2026

Healthcare · 2026

Business Services · 2026

Coverage notes

25 funds tracked, 301 portfolio companies (119 active · 182 realized). Verified weekly from public filings and deal announcements.

About Andera Partners

Andera Partners is a European mid-market private equity firm with €5.3 billion of assets under management as of December 2024, headquartered in Paris with offices in Munich and Brussels. The firm became independent in 2017 through a management-led spinoff from Edmond de Rothschild Group, building on a multi-decade track record across the underlying investment teams. Andera operates as a multi-strategy platform spanning LBO, growth equity, small-cap, mezzanine financing, energy transition infrastructure and life sciences venture.

Investment thesis

Andera deploys capital across six complementary strategies: Andera Acto (mid-cap LBO), Andera Croissance (growth equity), Andera Expansion (small-cap), Andera Mezzanine (debt-equity hybrid), Andera Smart Infra (energy transition infrastructure) and Andera Life Sciences (biotech venture and growth). Sector focus across the platform spans Healthcare (particularly biotech and HealthTech), TMT, Industrials, Real Estate, Telecom and Consumer, with the Life Sciences franchise providing dedicated expertise in early and growth-stage biotech transactions across European and selectively North American targets.

Recent activity

Recent realised exits include AgoMab (healthcare, 2026), Avalyn Pharma (healthcare, 2026), Tubulis (healthcare, 2026), Artemys (TMT, 2025), Evommune (healthcare, 2025) and Imcheck (healthcare, 2025), reflecting strong 2026 distribution momentum across the Life Sciences franchise. The platform tracks 26 funds, 119 active portfolio companies and 181 realised exits across multiple strategy types and vintages. Detailed buyer names and multiple data available on Pro at €49/month.